Evidence map›Paper›PMID 35183438›Full record

ArticleAcademic radiology2022

Development of a 3D CNN-based AI Model for Automated Segmentation of the Prostatic Urethra.

Mason J Belue, Stephanie A Harmon, Krishnan Patel, Asha Daryanani, Enis Cagatay Yilmaz, Peter A Pinto, Bradford J Wood, Deborah E Citrin, Peter L Choyke, Baris Turkbey

Open access · greenAbstract read
In one paragraph

Article in Academic radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Urethra contours on MRI: Multidisciplinary consensus educational atlas and reference standard for artificial intelligence benchmarking.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mason J BelueMolecular Imaging Branch (M.J.B., S.A.H., A.D., E.C.Y., P.L.C., B.T.), National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, Maryland.
Stephanie A HarmonMolecular Imaging Branch (M.J.B., S.A.H., A.D., E.C.Y., P.L.C., B.T.), National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, Maryland.
Krishnan PatelRadiation Oncology Branch (K.P., D.E.C.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Asha DaryananiMolecular Imaging Branch (M.J.B., S.A.H., A.D., E.C.Y., P.L.C., B.T.), National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, Maryland.
Enis Cagatay YilmazMolecular Imaging Branch (M.J.B., S.A.H., A.D., E.C.Y., P.L.C., B.T.), National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, Maryland.
Peter A PintoUrologic Oncology Branch (P.A.P.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Bradford J WoodCenter for Interventional Oncology (B.J.W.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Radiology (B.J.W.), Clinical Center, National Institutes of Health, Bethesda, Maryland.
Deborah E CitrinRadiation Oncology Branch (K.P., D.E.C.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Peter L ChoykeMolecular Imaging Branch (M.J.B., S.A.H., A.D., E.C.Y., P.L.C., B.T.), National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, Maryland.
Baris TurkbeyMolecular Imaging Branch (M.J.B., S.A.H., A.D., E.C.Y., P.L.C., B.T.), National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1182, Building 10, Room B3B85, Bethesda, Maryland. Electronic address: turkbeyi@mail.nih.gov.
National Institutes of Health · USNational Cancer Institute · USNational Institutes of Health Clinical Center · US

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
CCR Artificial Intelligence ResourceZIHBC012032 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$10.1M
Imaging, image guided biopsy and treatment of prostate cancerZIABC012062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$1.3M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

RATIONALE AND

objectiveThe combined use of prostate cancer radiotherapy and MRI planning is increasingly being used in the treatment of clinically significant prostate cancers. The radiotherapy dosage quantity is limited by toxicity in organs with de-novo genitourinary toxicity occurrence remaining unperturbed. Estimation of the urethral radiation dose via anatomical contouring may improve our understanding of genitourinary toxicity and its related symptoms. Yet, urethral delineation remains an expert-dependent and time-consuming procedure. In this study, we aim to develop a fully automated segmentation tool for the prostatic urethra. MATERIALS AND

methodsThis study incorporated 939 patients' T2-weighted MRI scans (train/validation/test/excluded: 657/141/140/1 patients), including in-house and public PROSTATE-x datasets, and their corresponding ground truth urethral contours from an expert genitourinary radiologist. The AI model was developed using MONAI framework and was based on a 3D-UNet. AI model performance was determined by Dice score (volume-based) and the Centerline Distance (CLD) between the prediction and ground truth centers (slice-based). All predictions were compared to ground truth in a systematic failure analysis to elucidate the model's strengths and weaknesses. The Wilcoxon-rank sum test was used for pair-wise comparison of group differences.

resultsThe overall organ-adjusted Dice score for this model was 0.61 and overall CLD was 2.56 mm. When comparing prostates with symmetrical (n = 117) and asymmetrical (n = 23) benign prostate hyperplasia (BPH), the AI model performed better on symmetrical prostates compared to asymmetrical in both Dice score (0.64 vs. 0.51 respectively, p < 0.05) and mean CLD (2.3 mm vs. 3.8 mm respectively, p < 0.05). When calculating location-specific performance, the performance was highest at the apex and lowest at the base location of the prostate for Dice and CLD. Dice location dependence: symmetrical (Apex, Mid, Base: 0.69 vs. 0.67 vs. 0.54 respectively, p < 0.05) and asymmetrical (Apex, Mid, Base: 0.68 vs. 0.52 vs. 0.39 respectively, p < 0.05). CLD location dependence: symmetrical (Apex, Mid, Base: 1.43 mm vs. 2.15 mm vs. 3.28 mm, p < 0.05) and asymmetrical (Apex, Mid, Base: 1.83 mm vs. 3.1 mm vs. 6.24 mm, p < 0.05).

conclusionWe developed a fully automated prostatic urethra segmentation AI tool yielding its best performance in prostate glands with symmetric BPH features. This system can potentially be used to assist treatment planning in patients who can undergo whole gland radiation therapy or ablative focal therapy.

Indexed as

Prostatic HyperplasiaProstatic NeoplasmsArtificial IntelligenceHumansMagnetic Resonance ImagingMaleProstateRadiotherapy DosageUrethrafocal therapyplanningprostateradiation therapyurethra

Identifiers

PMID35183438
PMCPMC9339453
OpenAlexW4212928906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.